ASXL1 and myelodysplastic syndrome: Focusing on the 142 lower‐risk patients (IPSS‐R score ≤ 3.5), ASXL1‐mutated patients exhibited a higher percentage of bone marrow blasts (p = 0.002), a greater number of mutant genes (p < 0.001), a higher percentage of MDS with excess blasts subtype (p = 0.037), and a higher IPSS‐M risk group (p < 0.001) (Table S5).